Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2b, Double-blind, Randomized, Placebo-controlled, Dose-finding, Multi-center, 36-week Safety and Efficacy Study With Open-label Extension (OLE) Period of Tesomet in Subjects With Hypothalamic Obesity

Next Previous
X
Search
Trial Profile

A Phase 2b, Double-blind, Randomized, Placebo-controlled, Dose-finding, Multi-center, 36-week Safety and Efficacy Study With Open-label Extension (OLE) Period of Tesomet in Subjects With Hypothalamic Obesity

Status: Suspended
Phase of Trial: Phase II

Latest Information Update: 21 Dec 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Metoprolol/tesofensine (Primary)
  • Indications Obesity
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Saniona

    • Most Recent Events

    • 09 Dec 2022 Planned End Date changed from 1 May 2024 to 9 Dec 2022.
    • 09 Dec 2022 Planned primary completion date changed from 1 Aug 2023 to 9 Dec 2022.
    • 29 Mar 2022 According to a Saniona media release, the decision to voluntarily pause the Phase 2b clinical trial of Tesomet for HO is not related to the safety or efficacy of Tesomet and is entirely due to funding limitations

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top